Anti-viral Research
NV-01 Dengue Fever Project
NV-01 Dengue Fever Project NV-01 is a flagship research project for the company in the field of plant-derived anti-virals.
In vitro experiments have demonstrated that the formula exhibits significant inhibitory effects against all four serotypes of the Dengue virus (DENV-1, DENV-2, DENV-3, and DENV-4), with viral inhibition rates reaching up to 99%.
The project is currently advancing through animal safety studies and is slated for IND (Investigational New Drug) clinical application pathways with China’s NMPA and the U.S. FDA, aiming to provide a potential innovative solution for global dengue prevention and control.
Cancer Recovery Support Research
NT-02 Research Project
NT-02 Research Project NT-02 focuses on the recovery phase following cancer treatment, providing physical support for patients through anti-inflammatory, antioxidant, and adaptogenic mechanisms.
This research project has gradually evolved into several specific product directions:
TolerCare
Aimed at overall recovery support after cancer treatment. Registration for Food for Special Medical Purposes (FSMP) is currently in progress.
MucoCare
Specifically designed for oral mucosal damage common during radiotherapy and chemotherapy, supporting the repair and restoration of the oral mucosa.
Continuous Product Validation
Our existing products undergo constant scientific scrutiny. For example, in laboratory studies against Human Coronavirus 229E, RESPIRATORY CLEAR Oral Spray achieved a 99.89% viral inhibition rate after only 30 minutes of contact.
Looking ahead, the company will further expand its research into other viral fields, including Norovirus (NV) and Respiratory Syncytial Virus (RSV).
